---
title: "Hicin Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 29.1577 million yuan, an increase of 17.87%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254135931.md"
description: "Hicin Pharmaceutical released its semi-annual report for 2025, with operating revenue of 309 million yuan, a year-on-year increase of 30.46%. The net profit attributable to the parent company was 29.1577 million yuan, a year-on-year increase of 17.87%. The net profit after deducting non-recurring gains and losses was 28.851 million yuan, a year-on-year increase of 13.07%. The basic earnings per share were 0.243 yuan"
datetime: "2025-08-22T09:36:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254135931.md)
  - [en](https://longbridge.com/en/news/254135931.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254135931.md)
---

# Hicin Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 29.1577 million yuan, an increase of 17.87%

According to the Zhitong Finance APP, Hicin Pharmaceutical (300584.SZ) released its semi-annual report for 2025, reporting an operating income of 309 million yuan, a year-on-year increase of 30.46%. The net profit attributable to shareholders of the listed company was 29.1577 million yuan, a year-on-year increase of 17.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 28.851 million yuan, a year-on-year increase of 13.07%. The basic earnings per share were 0.243 yuan

### Related Stocks

- [300584.CN](https://longbridge.com/en/quote/300584.CN.md)

## Related News & Research

- [Guriev: Russia is in need of a pipeline to China](https://longbridge.com/en/news/286935918.md)
- [Oil little changed as traders await breakthrough in US.-Iran negotiations](https://longbridge.com/en/news/286925961.md)
- [The Limits of Limit Orders in Retail FX/CFD Trading](https://longbridge.com/en/news/287126072.md)
- [10:19 ETAARC-360 Completes AICPA Peer Review with Pass Rating](https://longbridge.com/en/news/286929747.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)